Evaluation of Irisin as a Novel Diagnostic Marker for Early Detection and Progression of Diabetic Nephrophathy
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 200
- 主要终点
- Measure number of Participants With Diabetic nephropathy Adverse healthy people as Assessed by irisin hormone ).
研究概览
简要总结
Study the relation between irisin level and progression of diabetic nephropathy and its early detection.
详细描述
Diabetes is a prevalent worldwide challenge affecting 425 million individuals, with the International Diabetes Federation (IDF) projecting a rise to 630 million by 2045. Diabetic nephropathy (DN) is a critical complication that impacts one-third of diabetic patients and significantly contributes to cardiovascular morbidity and mortality, leading to substantial socioeconomic burdens (Dwivedi and Sikarwar, 2024).
Diabetic nephropathy (DN) is a multifaceted condition involving various interconnected mechanisms, primarily influenced by hyperglycemia .
Diabetic nephropathy (DN) is one of the most feared diabetic chronic microvascular complications and the major cause of end-stage renal disease (ESRD).
Therefore, early recognition is crucial. Presently, this relies on the albumin excretion rate (AER) and glomerular filtration rate (GFR).
Irisin, an exercise - induced myokine, has been linked to metabolic disorders, but its relationship with DN remains unclear.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 30 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 diabetic patients
排除标准
- •Non-diabetic kidney diseases.
- •Acute illness, infection, obesity, hypertension, type 1 DM.
- •Malignancy, other endocrine disorders, corticosteroid drugs, pregnancy, lactation.
结局指标
主要结局
Measure number of Participants With Diabetic nephropathy Adverse healthy people as Assessed by irisin hormone ).
时间窗: Two years
Participants With Diabetic nephropathy Adverse healthy people as Assessed by irisin hormone ).
次要结局
未报告次要终点
研究者
Gehad Hamdy Abdelmegid
Principle investigator
Sohag University